2.2 Cellular Inflammation, Mediators & Airway Remodeling

2.2 Cellular Inflammation, Mediators & Airway Remodeling

Quick Answer: Airway inflammation in asthma bifurcates into Type 2-high (eosinophilic, allergic/non-allergic) and non-Type 2 (neutrophilic or paucigranulocytic) endotypes. In Type 2 inflammation, epithelial alarmins (TSLP, IL-33, IL-25) activate dendritic cells, Th2 lymphocytes, and ILC2s. These cells secrete hallmark cytokines: IL-4 (drives IgE isotype switching), IL-5 (regulates eosinophil maturation and survival), and IL-13 (induces goblet cell metaplasia, hyperresponsiveness, and FeNO synthesis). Mast cell degranulation releases histamine and cysteinyl leukotrienes (1,000× more potent than histamine), while eosinophils unleash cytotoxic granule proteins. Over time, chronic activation of the epithelial-mesenchymal trophic unit (EMTU) drives irreversible subepithelial fibrosis, smooth muscle hyperplasia, and fixed airflow limitation.

Asthma is no longer viewed as a single homogeneous entity, but rather as a heterogeneous syndrome comprising diverse biological mechanisms termed endotypes. Understanding the cellular and molecular cascades of both Type 2-high and non-Type 2 inflammation is essential for the certified asthma educator to interpret diagnostic biomarkers, guide targeted biologic therapies, and explain the structural consequences of chronic disease.

---

The Inflammatory Endotypes: Type 2-High vs. Non-Type 2 Asthma

In contemporary clinical practice, asthma is stratified by underlying molecular endotype, which dictates both natural history and responsiveness to corticosteroids and monoclonal antibody therapies.

Asthma Endotype Classification:
├── Type 2-High (50%–70% of patients)
│     ├── Allergic / Atopic (Early-onset, aeroallergen-driven, Th2-mediated, high IgE)
│     └── Eosinophilic Non-Allergic (Late-onset, alarmin-driven, ILC2-mediated, high IL-5/IL-13)
│     └── Biomarkers: Blood eosinophils ≥150–300/μL, FeNO ≥25–50 ppb, elevated serum IgE
│     └── Therapeutic Response: High sensitivity to ICS and anti-Type 2 biologics
│
└── Non-Type 2 / Type 2-Low (30%–50% of patients)
      ├── Neutrophilic (Th1/Th17-driven, IL-8/IL-17, sputum neutrophils >60%–65%)
      └── Paucigranulocytic (Normal eosinophil and neutrophil counts; structural/neurogenic)
      └── Associations: Obesity, tobacco smoke, pollutants, recurrent infections, older adults
      └── Therapeutic Response: Poor sensitivity to ICS; steroid-resistant disease

1. Type 2-High Asthma

• Epidemiology: Represents 50% to 70% of children and adults with asthma.
• Subtypes: Includes classic early-onset allergic (atopic) asthma driven by adaptive T-helper 2 (Th2) lymphocytes, and late-onset non-atopic eosinophilic asthma driven by group 2 innate lymphoid cells (ILC2s).
• Pathobiology: Characterized by eosinophilic infiltration, elevated total and allergen-specific IgE, and increased nitric oxide production by airway epithelial cells.
• Clinical Biomarkers: Blood eosinophils $\ge 150\text{--}300\text{ cells/μL}$, sputum eosinophils $\ge 2%\text{--}3%$, fractional exhaled nitric oxide ($\text{FeNO}$) $\ge 25\text{--}50\text{ ppb}$, and positive allergen-specific IgE testing.
• Pharmacological Profile: Highly responsive to inhaled corticosteroids (ICS) and responsive to biologics targeting IgE, IL-5, IL-5Rα, IL-4Rα, and TSLP.

2. Non-Type 2 (Type 2-Low) Asthma

• Subtypes: Divided into neutrophilic asthma (defined by $>60%\text{--}65%$ neutrophils in induced sputum) and paucigranulocytic asthma (normal eosinophil and neutrophil proportions, representing uncoupled smooth muscle dysfunction).
• Pathobiology: Driven by T-helper 1 (Th1) and T-helper 17 (Th17) cells, alveolar macrophages, and structural cells producing interleukin-8 (IL-8 / CXCL8), interleukin-17A (IL-17A), and tumor necrosis factor-alpha (TNF-α). Neutrophils release human neutrophil elastase (HNE) and matrix metalloproteinase-9 (MMP-9), which degrade the extracellular matrix and induce mucus hypersecretion.
• Clinical Associations: Frequently encountered in adult-onset patients, active or passive cigarette smokers, patients with severe obesity, and those with chronic occupational pollutant exposures.
• Pharmacological Profile: Characteristically insensitive or resistant to corticosteroid therapy because corticosteroids inhibit neutrophil apoptosis, paradoxically prolonging neutrophil survival in the airways.

---

The Epithelial Sentinel: Upstream Alarmins and Antigen Presentation

The airway epithelium acts as an active immunological sentinel rather than a passive barrier. Inhaled environmental insults (aeroallergens, viral pathogens, cigarette smoke, diesel exhaust) trigger the rapid secretion of epithelial-derived cytokines termed alarmins:

1. Thymic Stromal Lymphopoietin (TSLP): An IL-7-like cytokine produced in response to epithelial injury. TSLP binds the TSLP receptor on CD11c+ myeloid dendritic cells, inducing upregulation of OX40 ligand (OX40L). When dendritic cells present processed allergen peptides via MHC Class II to naive CD4+ T cells, OX40L binds OX40, polarizing naive T cells into pro-allergic Th2 cells. TSLP also directly stimulates mast cells and ILC2s. It is the molecular target of the biologic Tezepelumab.
2. Interleukin-33 (IL-33): An IL-1 family cytokine stored preformed within epithelial cell nuclei and released upon cell necrosis or stress. IL-33 binds the ST2 receptor expressed at high levels on ILC2s, basophils, and mast cells, triggering massive, immediate secretion of IL-5 and IL-13 without requiring prior antigen sensitization.
3. Interleukin-25 (IL-25 / IL-17E): Secreted by damaged epithelial and specialized brush cells, IL-25 binds the IL-17RB receptor to amplify ILC2 proliferation and sustain downstream eosinophilic inflammation.

---

Comprehensive Cytokine Network and Inflammatory Cascade

The complex intercellular communication of asthma is mediated by a distinct network of cytokines and chemokines, each executing specialized physiological and pathological functions.

Major Inflammatory Mediators in Asthma

---

Mast Cells, IgE, and the Eicosanoid / Leukotriene Cascade

Tissue-resident mast cells in the airway mucosa and submucosa are the central effector cells of the early-phase asthmatic response (EAR) and key orchestrators of acute bronchospasm.

1. IgE Sensitization and Mast Cell Degranulation

• Sensitization: In allergic individuals, allergen-specific IgE produced by plasma cells binds with extremely high affinity ($K_d \approx 10^{-10}\text{ M}$) to $\text{FcεRI}$ receptors on the surface of mucosal mast cells and basophils.
• Activation: Upon subsequent inhalation of multivalent aeroallergens, the allergen bridges and cross-links adjacent $\text{IgE-FcεRI}$ complexes. This cross-linking activates Lyn and Syk tyrosine kinases, triggering intracellular calcium mobilization and explosive exocytosis of preformed cytoplasmic granules within minutes.
• Preformed Mediators:
  • Histamine: Binds $\text{H}_1$ receptors on bronchial smooth muscle to produce rapid, immediate bronchoconstriction; binds vascular endothelial $\text{H}_1$ receptors to cause postcapillary venular leakage and mucosal edema.
  • Tryptase: A neutral serine protease that cleaves structural basement membrane proteins, activates protease-activated receptor 2 (PAR-2) on surrounding epithelial and neural cells, and serves as an objective clinical biomarker of mast cell degranulation.

2. The Leukotriene Pathway (The 5-Lipoxygenase Cascade)

Following degranulation, mast cells, eosinophils, and alveolar macrophages synthesize potent lipid mediators de novo through the enzymatic breakdown of membrane phospholipids.

The Eicosanoid Biosynthetic Pathway:
Membrane Phospholipids
  │ (Cytosolic Phospholipase A2 [cPLA2])
  ▼
Arachidonic Acid
  ├── [5-Lipoxygenase (5-LO) + FLAP]
  │     └── Leukotriene A4 (LTA4)
  │           ├── [LTA4 Hydrolase] ───────────► Leukotriene B4 (LTB4) [Neutrophil Chemoattractant]
  │           └── [LTC4 Synthase + Glutathione]
  │                 └── Leukotriene C4 (LTC4)
  │                       └── [γ-Glutamyl Transferase] ─► Leukotriene D4 (LTD4)
  │                                                         └── [Dipeptidase] ─► Leukotriene E4 (LTE4)
  │                                                                                 │
  │                                                 [Cysteinyl Leukotrienes (CysLTs: LTC4, LTD4, LTE4)]
  │                                                 • Bind CysLT1 Receptor
  │                                                 • 1,000× more potent than histamine
  │                                                 • Sustained bronchospasm, edema, mucus hypersecretion
  │
  └── [Cyclooxygenase (COX-1 / COX-2)]
        └── Prostaglandin H2 (PGH2) ──────────► Prostaglandin D2 (PGD2) [Bronchospasm, Vasodilation]

• Potency and Receptors: The cysteinyl leukotrienes ($\text{LTC}_4$, $\text{LTD}_4$, and $\text{LTE}_4$) bind the $\text{CysLT}_1$ receptor on airway smooth muscle and microvascular endothelium. On a molar basis, cysteinyl leukotrienes are 1,000 times more potent than histamine at producing bronchoconstriction. Unlike histamine's transient effect (which peaks in 5–15 minutes), leukotriene-induced bronchoconstriction is sustained, lasting several hours.
• Pathological Effects: In addition to intense smooth muscle contraction, cysteinyl leukotrienes induce profound microvascular plasma extravasation, stimulate goblet cell mucin secretion, impair mucociliary transport, and recruit inflammatory leukocytes.
• Prostaglandin $\text{D}_2$ ($\text{PGD}_2$): Generated via the cyclooxygenase pathway, $\text{PGD}_2$ binds DP1, DP2 (CRTH2), and TP receptors, eliciting potent bronchoconstriction, peripheral vasodilation, and directed chemotaxis of Th2 cells, ILC2s, and eosinophils.

---

Eosinophil Effector Functions and Granule Toxicity

Circulating eosinophils are mobilized from the bone marrow by IL-5 and guided into the bronchial mucosa along chemokine gradients established by eotaxins (CCL11/eotaxin-1, CCL24/eotaxin-2, CCL26/eotaxin-3) binding to eosinophil CCR3 receptors. Once in the airway tissue, activated eosinophils release highly toxic cationic granule proteins that cause extensive epithelial denudation:

1. Major Basic Protein (MBP): Concentrated in the crystalline core of eosinophil granules. MBP is directly cytotoxic to respiratory epithelial cells, causing membrane pore formation, ciliostasis, and cell desquamation. Crucially, MBP acts as an allosteric antagonist of inhibitory muscarinic $\text{M}_2$ autoreceptors on postganglionic parasympathetic nerves. By disabling the normal negative feedback brake on acetylcholine release, MBP causes uninhibited acetylcholine release, leading to intense reflex hyperresponsiveness.
2. Eosinophil Peroxidase (EPO): Catalyzes the reaction between hydrogen peroxide and physiological halides (bromide and chloride), generating hypohalous acids (hypobromous acid) and reactive nitrogen species that produce severe oxidative tissue damage and cellular necrosis.
3. Eosinophil Cationic Protein (ECP) and Eosinophil-Derived Neurotoxin (EDN): Possess ribonuclease activity; they insert into target lipid membranes to form non-selective transmembrane channels, lysing structural cells and injuring sensory nerve fibers.

---

Airway Remodeling: Structural Alterations and Clinical Implications

Persistent cellular inflammation and recurrent tissue injury stimulate the Epithelial-Mesenchymal Trophic Unit (EMTU)—a dysregulated reparative cross-talk between injured basal epithelial cells and underlying subepithelial fibroblasts. Chronic release of profibrotic growth factors, notably Transforming Growth Factor-beta 1 (TGF-β1), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF), drives permanent airway remodeling.

Histological Hallmarks of Remodeling

1. Subepithelial Reticular Basement Membrane Thickening: Fibroblasts differentiate into contractile myofibroblasts, which deposit dense fibrillar collagens (Types I, III, and V), fibronectin, and tenascin beneath the true basal lamina, expanding the lamina reticularis from 3–5 μm to 10–25 μm.
2. Bronchial Smooth Muscle (BSM) Hypertrophy and Hyperplasia: BSM mass increases 2- to 3-fold. Furthermore, asthmatic smooth muscle cells undergo phenotypic switching from a purely contractile state to a proliferative, synthetic state that secretes inflammatory chemokines and matrix proteins.
3. Goblet Cell Metaplasia and Glandular Hypertrophy: Epithelial ciliated cells transdifferentiate into mucin-secreting goblet cells under the influence of IL-13, and submucosal glands hypertrophy, producing vast quantities of viscous MUC5AC.
4. Neoangiogenesis: VEGF drives the proliferation of enlarged, hyperpermeable capillary beds, increasing overall airway wall volume and baseline vascular congestion.

Clinical Implications of Airway Remodeling

• Accelerated Decline in Lung Function: Healthy non-smoking adults experience a physiological loss of $\text{FEV}_1$ of approximately 20–30 mL/year. Patients with chronically remodeled, uncontrolled asthma experience an accelerated decline of 40 to 60 mL/year.
• Fixed Airflow Limitation: Remodeling transforms variable, reversible obstruction into permanent, fixed airflow limitation that fails to meet bronchodilator reversibility criteria ($\ge 12%$ and $\ge 200\text{ mL}$ increase in $\text{FEV}_1$), often indistinguishable on spirometry from chronic obstructive pulmonary disease (COPD).
• Corticosteroid Resistance: Thickened, fibrotic airway walls and altered glucocorticoid receptor beta (GR-β) expression in severe remodeling diminish responsiveness to standard inhaled corticosteroid regimens, necessitating escalation to high-dose therapies, long-acting muscarinic antagonists (LAMAs), or targeted monoclonal biologics.